نتایج جستجو برای: hiv vaccine

تعداد نتایج: 309384  

Journal: :The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2009
Nancy A Wilson David I Watkins

The road to the discovery of a vaccine for HIV has been arduous and will continue to be difficult over the ensuing twenty years. Most vaccines are developed by inducing neutralizing antibodies against the target pathogen or by using attenuated strains of the particular pathogen to engender a variety of protective immune responses. Unfortunately, simple methods of generating anti-HIV antibodies ...

2014
Susan Zolla-Pazner Allan deCamp Peter B. Gilbert Constance Williams Nicole L. Yates William T. Williams Robert Howington Youyi Fong Daryl E. Morris Kelly A. Soderberg Carmela Irene Charles Reichman Abraham Pinter Robert Parks Punnee Pitisuttithum Jaranit Kaewkungwal Supachai Rerks-Ngarm Sorachai Nitayaphan Charla Andrews Robert J. O’Connell Zhi-yong Yang Gary J. Nabel Jerome H. Kim Nelson L. Michael David C. Montefiori Hua-Xin Liao Barton F. Haynes Georgia D. Tomaras

UNLABELLED In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variable regions 1 and 2 (V1V2) of the HIV-1 envelope glycoprotein gp120 were an inverse correlate of risk of HIV-1 infection. To determine if V1V2-specific Abs cross-react with V1V2 from different HIV-1 subtypes, if the nature of the V1V2 antigen used to asses cross-reactivity influenced infection risk, a...

Journal: :Current opinion in biotechnology 2004
Flavia Ferrantelli Aurelio Cafaro Barbara Ensoli

By the end of 2004, more than 20 HIV-1 vaccine candidates will have entered clinical testing in at least 30 trials worldwide. Almost half of these vaccines include nonstructural HIV-1 gene products. This represents an important innovation in the HIV vaccine field, because until 9 years ago not even preclinical testing in small animal models had been carried out with such immunogens. This review...

Journal: :Current opinion in HIV and AIDS 2010
Jerome H Kim Supachai Rerks-Ngarm Jean-Louis Excler Nelson L Michael

PURPOSE OF REVIEW An effective HIV vaccine is a global health priority. We describe lessons learned from four HIV vaccine trials that failed to demonstrate efficacy and one that showed modest protection as a pathway forward. RECENT FINDINGS The Merck Ad5 phase IIb T-cell vaccine failed to show efficacy and might have increased the risk of HIV acquisition in men who have sex with men. Although...

2010
Maria Goretti P. Fonseca Steven Forsythe Alexandre Menezes Shilpa Vuthoori Cristina Possas Valdiléa Veloso Francisca de Fátima Lucena John Stover

BACKGROUND The AIDS epidemic in Brazil remains concentrated in populations with high vulnerability to HIV infection, and the development of an HIV vaccine could make an important contribution to prevention. This study modeled the HIV epidemic and estimated the potential impact of an HIV vaccine on the number of new infections, deaths due to AIDS and the number of people receiving ARV treatment,...

2013
Muhammed O. Afolabi Jorjoh Ndure Abdoulie Drammeh Fatoumatta Darboe Shams-Rony Mehedi Sarah L. Rowland-Jones Nicola Borthwick Antony Black Gwen Ambler Grace C. John-Stewart Marie Reilly Tomáš Hanke Katie L. Flanagan

BACKGROUND A vaccine to decrease transmission of human immunodeficiency virus type 1 (HIV-1) during breast-feeding would complement efforts to eliminate infant HIV-1 infection by antiretroviral therapy. Relative to adults, infants have distinct immune development, potentially high-risk of transmission when exposed to HIV-1 and rapid progression to AIDS when infected. To date, there have been on...

Journal: :Vaccine 2006
Marc P Girard Saladin K Osmanov Marie Paule Kieny

Since the discovery of AIDS in 1981, the global spread of HIV has reached pandemic proportions, representing a global developmental and public health threat. The development of a safe, globally effective and affordable HIV vaccine offers the best hope for the future control of the pandemic. Significant progress has been made over the past years in the areas of basic virology, immunology, pathog...

Journal: :Public health reports 1988
A S Fauci P J Fischinger

The development of a safe and effective vaccine against infection by the human immunodeficiency virus (HIV) is of paramount importance to the prevention of AIDS worldwide. Although a great deal has been learned about HIV in a few short years, the development of an AIDS vaccine has proved to be extremely difficult. The lack of an appropriate animal model for AIDS, the absence of a defined protec...

2015
Gina M Graziani Jonathan B Angel

INTRODUCTION The development of an effective therapeutic HIV vaccine that induces immunologic control of viral replication, thereby eliminating or reducing the need for antiretroviral therapy (ART), would be of great value. Besides the obvious challenges of developing a therapeutic vaccine that would generate effective, sustained anti-HIV immunity in infected individuals is the issue of how to ...

2011
Eva Van Braeckel Patricia Bourguignon Marguerite Koutsoukos Frédéric Clement Michel Janssens Isabelle Carletti Alix Collard Marie-Ange Demoitié Gerald Voss Geert Leroux-Roels Lisa McNally

BACKGROUND This phase I/II partially blinded, randomized, dose-ranging study assessed the safety and immunogenicity of a novel human immunodeficiency virus type 1 (HIV-1) vaccine candidate consisting of a recombinant fusion protein (F4) containing 4 HIV-1 clade B antigens (Gag p24, Pol reverse transcriptase, Nef, and Gag p17) adjuvanted with AS01 in HIV-seronegative volunteers. Methods. Two dos...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید